凱普生物(300639.SZ):一季度淨利預增109.38%-144.27%
格隆匯3月31日丨凱普生物(300639.SZ)披露2022年第一季度業績預吿,預計2022年第一季度實現歸屬於上市公司股東的淨利潤3.60億元-4.20億元,同比增長109.38%-144.27%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3.56億元-4.16億元,同比增長118.29%-155.08%。
報吿期內,公司持續推進“核酸檢測產品+醫學檢驗服務”的一體化經營模式,持續推行“核酸99戰略”與“凱普B53核酸遠程戰略服務方案”,積極發揮公司產品技術和市場優勢,加強市場拓展。報吿期內,公司旗下第三方醫學實驗室(含香港)積極參與疫情防控,因核酸檢測需求增加對取樣耗材、核酸提取試劑等帶來銷售拉動,公司業務取得快速發展。
報吿期內,預計非經常性損益對公司淨利潤的影響金額約為400萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.